In Ph-positive B-ALL, a well-known mechanism of resistance is due to ABL1 kinase domain mutations, which hinder the binding of tyrosine kinase inhibitors (TKIs). The gene discussed is ABL1; the disease is acute lymphoblastic leukemia.